JP2022522815A - Ｔｓｇ－６抗体およびその用途 - Google Patents

Ｔｓｇ－６抗体およびその用途 Download PDF

Info

Publication number
JP2022522815A
JP2022522815A JP2021551926A JP2021551926A JP2022522815A JP 2022522815 A JP2022522815 A JP 2022522815A JP 2021551926 A JP2021551926 A JP 2021551926A JP 2021551926 A JP2021551926 A JP 2021551926A JP 2022522815 A JP2022522815 A JP 2022522815A
Authority
JP
Japan
Prior art keywords
seq
antibody
tsg
amino acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021551926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522815A5 (https=
Inventor
ブロックス，リチャード
エム． メイソン，ジャクリーン
アール． ブレイ，マーク
Original Assignee
ユニバーシティ ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ ヘルス ネットワーク filed Critical ユニバーシティ ヘルス ネットワーク
Publication of JP2022522815A publication Critical patent/JP2022522815A/ja
Publication of JP2022522815A5 publication Critical patent/JP2022522815A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021551926A 2019-03-12 2020-03-11 Ｔｓｇ－６抗体およびその用途 Pending JP2022522815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817152P 2019-03-12 2019-03-12
US62/817,152 2019-03-12
PCT/CA2020/050321 WO2020181376A1 (en) 2019-03-12 2020-03-11 Tsg-6 antibodies and uses therefor

Publications (2)

Publication Number Publication Date
JP2022522815A true JP2022522815A (ja) 2022-04-20
JP2022522815A5 JP2022522815A5 (https=) 2023-03-20

Family

ID=72427149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551926A Pending JP2022522815A (ja) 2019-03-12 2020-03-11 Ｔｓｇ－６抗体およびその用途

Country Status (14)

Country Link
US (1) US20220153834A1 (https=)
EP (1) EP3938389A4 (https=)
JP (1) JP2022522815A (https=)
KR (1) KR20210138674A (https=)
CN (1) CN113748130A (https=)
AU (1) AU2020234533A1 (https=)
BR (1) BR112021017810A2 (https=)
CA (1) CA3129302A1 (https=)
EA (1) EA202192488A1 (https=)
IL (1) IL286216A (https=)
MX (1) MX2021010766A (https=)
SG (1) SG11202109708TA (https=)
TW (1) TW202100551A (https=)
WO (1) WO2020181376A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023192829A2 (en) * 2022-03-28 2023-10-05 University Of Florida Research Foundation, Incorporated Alpha-1 antitrypsin z- and m-specific binding proteins
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
KR102582500B1 (ko) 2022-10-27 2023-09-26 서울대학교산학협력단 Tnfaip6 -조작된 종양 세포 및 이의 이용
WO2024102759A1 (en) * 2022-11-07 2024-05-16 Board Of Regents, The University Of Texas System Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
PT3186281T (pt) * 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEM CELL RESEARCH & THERAPY, vol. 9, no. 173, JPN6024010481, 2018, pages 1 - 26, ISSN: 0005432202 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 1, JPN6024010480, 2013, pages 412 - 422, ISSN: 0005283816 *

Also Published As

Publication number Publication date
CA3129302A1 (en) 2020-09-17
AU2020234533A1 (en) 2021-09-16
MX2021010766A (es) 2021-12-10
TW202100551A (zh) 2021-01-01
SG11202109708TA (en) 2021-10-28
US20220153834A1 (en) 2022-05-19
CN113748130A (zh) 2021-12-03
WO2020181376A1 (en) 2020-09-17
IL286216A (en) 2021-10-31
EP3938389A4 (en) 2022-11-09
BR112021017810A2 (pt) 2021-11-23
EA202192488A1 (ru) 2022-02-08
EP3938389A1 (en) 2022-01-19
KR20210138674A (ko) 2021-11-19

Similar Documents

Publication Publication Date Title
US11274142B2 (en) Fusion protein containing TGF-β receptor and medicinal uses thereof
TWI838621B (zh) 具有經修飾重鏈恆定區之多特異性重鏈抗體
CN115894703A (zh) 具有经修饰重链恒定区的多特异性重链抗体
JP7596298B2 (ja) 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2022522815A (ja) Ｔｓｇ－６抗体およびその用途
CN111133007A (zh) 与胞外酶结合的重链抗体
JP2023549851A (ja) 葉酸受容体アルファに結合する重鎖抗体
JP2022517809A (ja) Ｌｉｌｒｂ３結合分子とその使用
CN116199778B (zh) 抗4-1bb抗体及其用途
JP2022520817A (ja) Ｆｃｍｒ結合分子およびそれらの使用
WO2023186100A1 (zh) 抗ror1的抗体及其用途
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN115181180B (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
CN118974097A (zh) 抗psma抗体、其变体及其用途
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
KR20220167336A (ko) 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CN116323658A (zh) 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008